AM
Therapeutic Areas
Aldeyra Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Reproxalap | Dry Eye Disease (Signs & Symptoms) | Phase 3 |
| ADX-2191 | Primary Vitreoretinal Lymphoma | Phase 3 (likely) |
| ADX-629 | Systemic Immune-Mediated & Metabolic Diseases | Phase 1/Phase 2 (implied) |
Leadership Team at Aldeyra Therapeutics
TC
Todd C. Brady
Appears as Senior Author/Executive (likely CEO/CSO)
DC
David Clark
Clinical Investigator/Author
JS
John Sheppard
Clinical Investigator/Author
PK
Paul Karpecki
Clinical Investigator/Author
BC
Bill Cavanagh
Scientist/Author
CE
Christopher E. Starr
Clinical Investigator/Author
KK
Kelly K. Nichols
Clinical Investigator/Author
JT
Joseph Tauber
Clinical Investigator/Author
KJ
Kenneth J. Mandell
Clinical Investigator/Author
DS
David S. Chu
Clinical Investigator/Author